Publication:
Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome

Placeholder

Organizational Units

Authors

Kurt, Ender
Evrensel, Türkkan
Manavoğlu, Osman

Authors

Sezgin, Canfeza
Özdemir, Necmettin
Göker, Erdem

Advisor

Language

Publisher:

Lippincott Williams & Wilkins

Journal Title

Journal ISSN

Volume Title

Abstract

Objective: Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes. Materials and Methods: In this study, the efficacy and safety of lower dose capecitabine (2000 Mg/m(2)/d) in patients with anthra-cycline- and taxane-pretreated MBC were studied with a special emphasis on the potential predictors of time to tumor progression (TTP) and response to the capecitabine treatment. Results: The overall response rate (ORR) was 17%. The median TTP was 5 months. Among various factors analyzed, univariate analysis showed that a performance status (PS) of 2 and the presence of visceral metastases were inversely correlated with TTP. Multivariate analysis showed that a poor PS score was associated with impaired TTP. Conclusions: Our study indicates that lower dose capecitabine has substantial antitumor activity and a favorable safety profile in the treatment of anthracycline- and taxane-pretreated MBC. Also, only performance score was demonstrated to be a significant parameter affecting TTP.

Description

Source:

Keywords:

Keywords

General & internal medicine, Capecitabine, Metastatic breast cancer, Multicenter Phase II, Carcinoma, Amplification, Safety

Citation

Sezgin, C. vd. (2007). "Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome". Southern Medical Journal, 100(1), 27-32.

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads